Auro Laboratories Limited (AUROLAB.BO)
- Previous Close
274.10 - Open
263.00 - Bid 269.00 x --
- Ask 274.25 x --
- Day's Range
263.00 - 277.00 - 52 Week Range
170.00 - 300.00 - Volume
1,408 - Avg. Volume
4,749 - Market Cap (intraday)
1.702B - Beta (5Y Monthly) 0.16
- PE Ratio (TTM)
92.59 - EPS (TTM)
2.95 - Earnings Date Aug 7, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, that includes potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid. In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; 3,4,5 - trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram. It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India.
www.aurolabs.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AUROLAB.BO
View MorePerformance Overview: AUROLAB.BO
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AUROLAB.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AUROLAB.BO
View MoreValuation Measures
Market Cap
1.70B
Enterprise Value
2.07B
Trailing P/E
92.59
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.78
Price/Book (mrq)
3.96
Enterprise Value/Revenue
10.66
Enterprise Value/EBITDA
50.94
Financial Highlights
Profitability and Income Statement
Profit Margin
9.48%
Return on Assets (ttm)
1.56%
Return on Equity (ttm)
4.33%
Revenue (ttm)
193.98M
Net Income Avi to Common (ttm)
18.39M
Diluted EPS (ttm)
2.95
Balance Sheet and Cash Flow
Total Cash (mrq)
6.3M
Total Debt/Equity (mrq)
104.76%
Levered Free Cash Flow (ttm)
-193.18M